| 07/02/2026 7:26 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/29/2026 6:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/29/2026 4:29 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:30 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:30 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:39 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/22/2026 5:59 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 6:02 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
Get the Latest News and Ratings for HOWL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/16/2026 5:01 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 7:16 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/11/2026 7:13 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/10/2026 4:20 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 5:13 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 5:42 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 5:51 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/28/2026 4:02 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:04 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/26/2026 5:18 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/20/2026 5:08 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 4:01 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:01 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:03 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/14/2026 4:23 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/13/2026 3:06 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/12/2026 6:56 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/12/2026 6:47 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/12/2026 5:26 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/11/2026 3:31 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Trump's New Dollar (Ad) Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening.
The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. Watch the free briefing and see the three steps to prepare today |
| 05/11/2026 3:33 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:33 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/07/2026 5:22 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/05/2026 6:04 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/04/2026 5:00 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 3:52 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 6:16 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/29/2026 3:47 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:59 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/27/2026 6:07 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/27/2026 6:12 AM | Werewolf Therapeutics (1785530) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/24/2026 4:26 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/11/2026 2:46 PM | Longwood Fund III, L.P. (1640546) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13G/A | |
| 02/06/2026 3:41 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/20/2026 3:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/16/2026 4:36 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 01/15/2026 4:22 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/12/2026 4:09 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 4:12 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:58 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:59 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:54 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:54 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:56 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:57 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/02/2026 4:32 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 5:59 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 12/29/2025 4:27 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 3:45 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:45 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:46 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:47 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:47 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:48 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:55 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. Get the name and ticker of Louis Navellier's #1 AI stock free |
| 12/22/2025 3:56 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:56 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:56 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:57 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:57 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/18/2025 7:24 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/17/2025 5:28 PM | Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/17/2025 5:28 PM | EVNIN LUKE (1134657) Reporting EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 4:32 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |